Aduro Biotech, Inc. (ADRO): Price and Financial Metrics
ADRO Price/Volume Stats
|Current price||$14.60||52-week high||$20.20|
|Prev. close||$14.01||52-week low||$4.51|
|Day high||$14.86||Avg. volume||162,237|
|50-day MA||$13.39||Dividend yield||N/A|
|200-day MA||$12.74||Market Cap||236.70M|
ADRO Stock Price Chart Interactive Chart >
Aduro Biotech, Inc. (ADRO) Company Bio
Aduro Biotech is a clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. The company was founded in 2000 and is based in Berkeley, California.
ADRO Latest News Stream
|Loading, please wait...|
ADRO Latest Social Stream
View Full ADRO Social Stream
Latest ADRO News From Around the Web
Below are the latest news stories about Aduro Biotech Inc that investors may wish to consider to help them evaluate ADRO as an investment opportunity.
Aduro Biotech, American Renal Associates leads healthcare gainers; Benitec Biopharma, Mesoblast among major losers
Gainers: Aduro Biotech (ADRO) +442%, American Renal Associates (ARA) +69%, Nano-X Imaging (NNOX) +38%, CTI BioPharma (CTIC) +18%, ProPhase Labs (PRPH) +16%.Losers: Benitec Biopharma (BNTC) -36%, Mesoblast (MESO) -36%, Arcutis Biotherapeutics (ARQT) -14%, PDL BioPharma (PDLI) -13%, Electromed (ELMD) -12%....
Gainers: Aduro Biotech (ADRO) +20%. Otonomy (OTIC) +14%. BeyondSpring (BYSI) +13%. Verrica Pharmaceuticals (VRCA) +13%. STRATA Skin Sciences (SSKN) +11%.Losers: Poseida Therapeutics (PSTX) -30%. Acer Therapeutics (ACER) -20%. Biofrontera (BFRA) -15%. Unity Biotechnology (UBX) -11%. Interpace Biosciences (IDXG) -10%....
BERKELEY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing…
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the first patient with IgA nephropathy has been dosed in a Phase 1 clinical trial of BION-1301, an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors. “We are thrilled to have dosed the first patient with IgA nephropathy in the Phase 1 clinical study of our investigational anti-APRIL antibody, BION-1301,” said Dimitry S.A. Nuyten, M.D., Ph.D., chief medical officer of Aduro.
ADRO Price Returns